Anna Kamocka1, Swathikan Chidambaram2, Simon Erridge2, Gauri Vithlani2, Alexander Dimitri Miras3,4, Sanjay Purkayastha2. 1. Department of Metabolism, Digestion and Reproduction, Hammersmith Hospital, Imperial College London, 6th Floor Commonwealth Building, Du Cane Road, London, W12 0NN, UK. akamocka@nhs.net. 2. Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK. 3. Department of Metabolism, Digestion and Reproduction, Hammersmith Hospital, Imperial College London, 6th Floor Commonwealth Building, Du Cane Road, London, W12 0NN, UK. 4. School of Medicine, Ulster University, London, UK.
Abstract
BACKGROUND: Roux-en-Y gastric bypass (RYGB) is a gold-standard procedure for treatment of obesity and associated comorbidities. No consensus on the optimal design of this operation has been achieved, with various lengths of bypassed small bowel limb lengths being used by bariatric surgeons. This aim of this systematic review and meta-analysis was to determine whether biliopancreatic limb (BPL) length in RYGB affects postoperative outcomes including superior reduction in weight, body mass index (BMI), and resolution of metabolic comorbidities associated with obesity. METHODS: A systematic search of the literature was conducted up until 1st June 2021. Meta-analysis of primary outcomes was performed utilising a random-effects model. Statistical significance was determined by p value < 0.05. RESULTS: Ten randomised controlled trials were included in the final quantitative analysis. No difference in outcomes following short versus long BLP in RYGB was identified at 12-72 months post-operatively, namely in BMI reduction, remission or improvement of type 2 diabetes mellitus, hypertension, dyslipidaemia, and complications (p > 0.05). Even though results of four studies showed superior total body weight loss in the long BPL cohorts at 24 months post-operatively (pooled mean difference -6.92, 95% CI -12.37, -1.48, p = 0.01), this outcome was not observed at any other timepoint. CONCLUSION: Based on the outcomes of the present study, there is no definitive evidence to suggest that alteration of the BPL affects the quantity of weight loss or resolution of co-existent metabolic comorbidities associated with obesity.
BACKGROUND: Roux-en-Y gastric bypass (RYGB) is a gold-standard procedure for treatment of obesity and associated comorbidities. No consensus on the optimal design of this operation has been achieved, with various lengths of bypassed small bowel limb lengths being used by bariatric surgeons. This aim of this systematic review and meta-analysis was to determine whether biliopancreatic limb (BPL) length in RYGB affects postoperative outcomes including superior reduction in weight, body mass index (BMI), and resolution of metabolic comorbidities associated with obesity. METHODS: A systematic search of the literature was conducted up until 1st June 2021. Meta-analysis of primary outcomes was performed utilising a random-effects model. Statistical significance was determined by p value < 0.05. RESULTS: Ten randomised controlled trials were included in the final quantitative analysis. No difference in outcomes following short versus long BLP in RYGB was identified at 12-72 months post-operatively, namely in BMI reduction, remission or improvement of type 2 diabetes mellitus, hypertension, dyslipidaemia, and complications (p > 0.05). Even though results of four studies showed superior total body weight loss in the long BPL cohorts at 24 months post-operatively (pooled mean difference -6.92, 95% CI -12.37, -1.48, p = 0.01), this outcome was not observed at any other timepoint. CONCLUSION: Based on the outcomes of the present study, there is no definitive evidence to suggest that alteration of the BPL affects the quantity of weight loss or resolution of co-existent metabolic comorbidities associated with obesity.
Authors: Philip R Schauer; Sangeeta R Kashyap; Kathy Wolski; Stacy A Brethauer; John P Kirwan; Claire E Pothier; Susan Thomas; Beth Abood; Steven E Nissen; Deepak L Bhatt Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: Bent J Nergård; Andreas Lindqvist; Hjörtur G Gislason; Leif Groop; Mikael Ekelund; Nils Wierup; Jan L Hedenbro Journal: Surg Obes Relat Dis Date: 2015-04-02 Impact factor: 4.734
Authors: Kamal K Mahawar; Parveen Kumar; Chetan Parmar; Yitka Graham; William R J Carr; Neil Jennings; Norbert Schroeder; Shlok Balupuri; Peter K Small Journal: Obes Surg Date: 2016-03 Impact factor: 4.129
Authors: Carel W le Roux; Simon J B Aylwin; Rachel L Batterham; Cynthia M Borg; Frances Coyle; Vyas Prasad; Sandra Shurey; Mohammad A Ghatei; Ameet G Patel; Stephen R Bloom Journal: Ann Surg Date: 2006-01 Impact factor: 12.969
Authors: A Pucci; U Tymoszuk; W H Cheung; J M Makaronidis; S Scholes; G Tharakan; M Elkalaawy; M Guimaraes; M Nora; M Hashemi; A Jenkinson; M Adamo; M P Monteiro; N Finer; R L Batterham Journal: Diabet Med Date: 2017-11-21 Impact factor: 4.359